Algeta to stop phase III ALSYMPCA trial of Alpharadin based on statistically significant efficacy June 6, 2011
ImmunoCellular Therapeutics to use BioWa's Potelligent technology for anticancer antibodies June 6, 2011
AVEO and Centocor Ortho Biotech enter license agreement for antibodies targeting MSP receptor June 3, 2011
Bristol-Myers Squibb and Roche enter agreement to evaluate ipilimumab/vemurafenib combination June 3, 2011
RSS